Systems in depth
One section per system: its state at evidence close, its exposures and what the operational series will watch.
Contents
- ·Edition home
- ·Executive summary
- 1Neurotechnology is clinical hardware and a new class of personal data
- 2Key findings
- 3Systems and sectors at baseline
- 4Risks and capability
- 5Consumer neural data outside medical rules
- 6Readings from the other desks
- 7The 2027 agenda
- 8Systems in depth
- Aপদ্ধতি
- BData appendix
- CReferences and record
- ·Complete edition, for print
8.1Interface hardware and decoding platforms
Interfaces record from implanted electrodes, from the brain surface or from inside a blood vessel, and decode with trained models. Evidence is strongest where peer review exists, and weakest where claims rest on company statements.
| Component | অবস্থা | প্রমাণ | অবস্থা |
|---|---|---|---|
| Intracortical arrays | speech decoded at 62 to 78 words per minute and 97.5% accuracy beyond eight months in single participants | 12346 | Reported |
| Endovascular arrays | five participants recorded for one year, preprint | 8 | Reported |
| Cortical-surface arrays | a company reported clearance for up to 30 days; another reported an IDE for a two-participant early feasibility study in 2025, from company material | 1527 | Reported |
| Closed-loop stimulation and wearables | an adaptive deep brain stimulation system was approved in 2025 per the company; a wearable wrist interface paper appeared in 2025; a visual prosthesis designation of 2024 is a company statement reported by trade press | 283244 | Inferred |
Couplings
- INF → HLT clinical benefit
- INF → DAT neural signals as data
- BIO ↔ INF tissue response
Evidence to bind in 2027
- claims on a common basis
- participants beyond single studies
Related editions
- GLB Global Systems
- GS-04 Health and One Health
- GS-13 Cyber and Digital Systems
- XT-10 Cybersecurity and Advanced Cryptography
- XT-12 Advanced Materials and Nanotechnology
- XT-01 Artificial Intelligence and Agentic Systems
8.2Power, heat and data of implants
An implant must be powered, kept cool enough for tissue and moved off the body as data. No power or heat budget was bound in this edition.
| Component | অবস্থা | প্রমাণ | অবস্থা |
|---|---|---|---|
| Power and charging | no budget bound; guidance asks for non-clinical testing of implanted interfaces | 9 | NOT BOUND |
| তাপ | no limit or measurement bound; an implantable neurostimulator standard exists | 40 | NOT BOUND |
| Data volume and radio links | channel counts known for two studies; data rates not bound | 38 | Inferred |
| Cooling water | no documented coupling | 9 | Expert input |
Couplings
- ENE → INF implant power
- INF → BIO heat and tissue
- INF → DAT data off the body
Evidence to bind in 2027
- power and heat budgets by platform
- data rates and radio limits
Related editions
- GLB Global Systems
- GS-04 Health and One Health
- GS-13 Cyber and Digital Systems
- XT-10 Cybersecurity and Advanced Cryptography
- XT-12 Advanced Materials and Nanotechnology
- XT-01 Artificial Intelligence and Agentic Systems
8.3Materials, durability and fabrication
Electrodes sit in tissue for years. Signal loss, drift and biocompatibility are open problems in the literature, and fabrication dependence is not bound here.
| Component | অবস্থা | প্রমাণ | অবস্থা |
|---|---|---|---|
| Electrode materials | a materials roadmap for neural interfaces exists | 23 | Reported |
| Biocompatibility | long-term biocompatibility and signal resolution remain to be improved | 24 | Reported |
| Decoder drift | accuracy falls as neurons turn over; methods correct for it | 22 | Reported |
| Fabrication | capacity by country not bound; policy targets name electrodes and chips | 16 | Inferred |
Couplings
- BIO ↔ INF biocompatibility
- MIN → INF materials
- TRD → INF industrial policy
Evidence to bind in 2027
- device failure rates
- materials dependence by platform
Related editions
- GLB Global Systems
- GS-04 Health and One Health
- GS-13 Cyber and Digital Systems
- XT-10 Cybersecurity and Advanced Cryptography
- XT-12 Advanced Materials and Nanotechnology
- XT-01 Artificial Intelligence and Agentic Systems
8.4Economy, investment and workforce
Company rounds are large and rest on company statements. Market size depends on definition, and workforce numbers are not bound.
| Component | অবস্থা | প্রমাণ | অবস্থা |
|---|---|---|---|
| Company funding | a USD 650 million round in June 2025 with a press-reported pre-money valuation of about USD 9 billion; another company reported a Series D round in November 2025 | 2030 | Reported |
| Trial scale | registry estimate of 15; company statement of 5 in June 2025; a company statement of 21 in January 2026 as reported by a news agency | 132026 | Reported |
| Market size | trade sources differ widely by definition; none bound | 29 | NOT BOUND |
| Industry policy | two to three cluster zones by 2027 and two to three leading enterprises by 2030 | 16 | Reported |
Couplings
- FIN → INF scale-up
- GOV → FIN industrial policy
- HLT → INF clinical workforce
Evidence to bind in 2027
- market size on a common definition
- workforce size and skills gaps
Related editions
- GLB Global Systems
- GS-04 Health and One Health
- GS-13 Cyber and Digital Systems
- XT-10 Cybersecurity and Advanced Cryptography
- XT-12 Advanced Materials and Nanotechnology
- XT-01 Artificial Intelligence and Agentic Systems
8.5Neural data, security and governance watch
The nearest effect of neurotechnology on other systems is on privacy law. Rules differ by place, and several apply only to data used for identification.
| Component | অবস্থা | প্রমাণ | অবস্থা |
|---|---|---|---|
| Global ethics | UNESCO Recommendation adopted November 2025; OECD Recommendation of December 2019 | 1031 | Reported |
| United States federal | FDA guidance of 2021; MIND Act bill in committee | 91112 | Reported |
| United States states | Colorado in force 7 August 2024; California in force 1 January 2025 per the sponsor; Montana from 1 October 2025 and Connecticut mostly from 1 July 2026 per a privacy forum tracker | 142541 | Reported |
| Chile and others | constitutional rule, 2023 deletion order, pending neurorights bill; inferred data a grey zone; EU device and AI rules | 1718423943 | Reported |
| Advocacy and ethics | proposals for a moratorium on non-medical implants and a mental privacy framework; a 2024 consumer report on 30 companies | 1921333435 | Reported |
Couplings
- INF → DAT neural data
- GOV → DAT rules
- GOV → FIN compliance cost
Evidence to bind in 2027
- text of national laws
- consumer practices by company
Related editions
- GLB Global Systems
- GS-04 Health and One Health
- GS-13 Cyber and Digital Systems
- XT-10 Cybersecurity and Advanced Cryptography
- XT-12 Advanced Materials and Nanotechnology
- XT-01 Artificial Intelligence and Agentic Systems
Notes
Numbers are the edition’s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. Annex C, references
- 3Card, N.S. et al., An accurate and rapidly calibrating speech neuroprosthesis, medRxiv preprint, 26 December 2023 (preprint record read: 99.6% on 50 words on day 1; 90.2% on 125,000 words on day 2; 97.5% beyond eight months; 256 electrodes; the record notes the New England Journal of Medicine version 391(7), 609 to 618, August 2024). Cold Spring Harbor Laboratory, New York. Observation year 2023. Accessed 2026-11-03.back
- 8Chetty, N. et al., Signal properties and stability of a chronically implanted endovascular brain computer interface, medRxiv preprint, 25 September 2025 (preprint record read: five participants; 16-channel array; one year; not peer reviewed). Cold Spring Harbor Laboratory, New York. Observation year 2025. Accessed 2026-11-03.back
- 7Lorach, H. et al., Walking naturally after spinal cord injury using a brain-spine interface, Nature 618(7963), 126 to 133, published online 24 May 2023 (reference record read: fully implanted; stable for over one year; one man with chronic tetraplegia). Springer Nature, London. Observation year 2023. Accessed 2026-11-03.back
- 1Willett, F.R. et al., A high-performance speech neuroprosthesis, Nature 620(7976), 1031 to 1036, published online 23 August 2023 (reference record read: 62 words per minute; 23.8% word error rate on 125,000 words; 9.1% on 50 words). Springer Nature, London. Observation year 2023. Accessed 2026-11-03.back
- 2Metzger, S.L. et al., A high-performance neuroprosthesis for speech decoding and avatar control, Nature 620(7976), 1037 to 1046, published online 23 August 2023 (reference record read: median 78 words per minute; median word error rate 25%). Springer Nature, London. Observation year 2023. Accessed 2026-11-03.back
- 4Wairagkar, M. et al., An instantaneous voice synthesis neuroprosthesis, bioRxiv preprint, 19 August 2024 (preprint record read: 256 microelectrodes, one participant with ALS; no quantitative scores in the abstract; the record notes Nature 644(8075), 145 to 152, 2025). Cold Spring Harbor Laboratory, New York. Observation year 2024. Accessed 2026-11-03.back
- 6Willett, F.R., Avansino, D.T., Hochberg, L.R., Henderson, J.M. and Shenoy, K.V., High-performance brain-to-text communication via handwriting, Nature 593(7858), 249 to 254, published online 12 May 2021 (reference record read: 90 characters per minute; 94.1% raw online accuracy). Springer Nature, London. Observation year 2021. Accessed 2026-11-03.back
- 15Precision Neuroscience (ed.), company release on FDA 510(k) clearance of the Layer 7 Cortical Interface, 17 April 2025 (release read; vendor announcement, weak evidence: up to 30 days of implantation; 37 patients tested). Precision Neuroscience, New York. Observation year 2025. Accessed 2026-11-03.back
- 27Paradromics (ed.), Paradromics Receives FDA Approval for the Connect-One Clinical Study with the Connexus Brain-Computer Interface (company release of November 2025, read as reposted by BioSpace; IDE approval for an early feasibility study that will initially enrol two participants at three sites). Company statement, weak evidence. Paradromics, Austin. Observation year 2025. Accessed 2026-11-05.back
- 28Medtronic (ed.), Medtronic receives FDA approval for BrainSense Adaptive DBS technology (company release republished by News-Medical, 3 March 2025; FDA approval of adaptive deep brain stimulation and the BrainSense Electrode Identifier for Parkinson disease). Company statement, weak evidence. Medtronic, Dublin. Observation year 2025. Accessed 2026-11-05.back
- 32Kaifosh, P., Reardon, T.R. and CTRL-labs at Reality Labs, A generic non-invasive neuromotor interface for human-computer interaction, Nature 645, 702 to 711, 2025 (Crossref record). Springer Nature, London. Observation year 2025. Accessed 2026-11-05.back
- 44Holt, K., Neuralink says the FDA designated its Blindsight implant as a breakthrough device (Engadget, 18 September 2024; company statement as reported). Trade press reporting a vendor announcement, weak evidence. Engadget, New York. Observation year 2024. Accessed 2026-11-05.back
- 11United States Senate (ed.), Management of Individuals Neural Data Act of 2025 (MIND Act), S. 2925, 119th Congress, introduced text (text read: FTC study and report within one year of enactment; USD 10 million authorised; referred to committee). US Government Publishing Office, Washington. Observation year 2025. Accessed 2026-11-03.back
- 9US Food and Drug Administration (ed.), Implanted Brain-Computer Interface (BCI) Devices for Patients with Paralysis or Amputation: Non-clinical Testing and Clinical Considerations, final guidance, May 2021 (guidance page read). Center for Devices and Radiological Health, Silver Spring. Observation year 2021. Accessed 2026-11-03.back
- 40ISO (ed.), ISO 14708-3:2017 Implants for surgery, Active implantable medical devices, Part 3: Implantable neurostimulators (ISO open-data deliverables record: published 12 April 2017; current, confirmed). International Organization for Standardization, Geneva. Observation year 2017. Accessed 2026-11-05.back
- 23Wellman, S.M. et al., A materials roadmap to functional neural interface design, Advanced Functional Materials 28(12), 2018 (reference record read; no figures in the abstract). Wiley, Weinheim. Observation year 2018. Accessed 2026-11-03.back
- 24Feng, Y. et al., Brain-computer interfaces: the dawn of a new era in disease treatment, Exploration 6(3), 2026 (reference record read: electrode biocompatibility and signal resolution named as challenges). Wiley, Beijing. Observation year 2026. Accessed 2026-11-03.back
- 22Ma, X. et al., Using adversarial networks to extend brain computer interface decoding accuracy over time, eLife 12, e84296, 2023 (reference record read). eLife Sciences, Cambridge. Observation year 2023. Accessed 2026-11-03.back
- 16Ministry of Industry and Information Technology and six other bodies (eds.), Implementation Opinions on Promoting the Innovation and Development of the Brain-Computer Interface Industry, MIIT (2025) No. 164, 23 July 2025, English translation by the Center for Security and Emerging Technology, 18 December 2025 (translation page read). Georgetown University, Washington. Observation year 2025. Accessed 2026-11-03.back
- 20Zeff, M., Elon Musk Neuralink closes a USD 650 million Series E (trade report, 2 June 2025; page read; vendor statement as reported: five people implanted; valuation of about USD 9 billion pre-money from an earlier press report). TechCrunch, San Francisco. Observation year 2025. Accessed 2026-11-03.back
- 13ClinicalTrials.gov (ed.), PRIME: An Early Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices, NCT06429735 (record read: recruiting; start 9 January 2024; estimated enrolment 15; updated January 2026; sponsor-supplied entry). National Library of Medicine, Bethesda. Observation year 2026. Accessed 2026-11-03.back
- 30Synchron (ed.), Synchron Raises USD 200 Million Series D to Advance Brain-Computer Interface Technology (Business Wire release as reproduced by I-Connect007, 7 November 2025; total funding USD 345 million). Company statement, weak evidence; no figure used. Synchron, New York. Observation year 2025. Accessed 2026-11-05.back
- 26Santhosh, C., Elon Musk’s Neuralink says it has 21 participants enrolled in trials (Reuters, 28 January 2026, read as published by The Star; company statement of 21 participants enrolled worldwide, up from 12 in September 2025). News agency report of a company statement, weak evidence. Reuters, London. Observation year 2026. Accessed 2026-11-05.back
- 29Mordor Intelligence (ed.), Brain-computer Interface Market Size and Share Analysis (report page updated 3 August 2026; USD 1.27 billion in 2025) and TechSci Research (ed.), Brain Computer Interface Market (report page, January 2026; USD 2.57 billion in 2025). Market-research pages, weak evidence; figures differ about twofold and none is used. Observation year 2025. Accessed 2026-11-05.back
- 12US Senate Committee on Commerce, Science, and Transportation (ed.), release on the introduction of the MIND Act, 24 September 2025 (release read: names Colorado, California, Montana and Connecticut as states with neural data laws). US Senate, Washington. Observation year 2025. Accessed 2026-11-03.back
- 10UNESCO (ed.), Recommendation on the Ethics of Neurotechnology (page read: adopted November 2025 at the 43rd session of the General Conference; mandate entrusted by 194 Member States in 2023; the page states no neural data provisions). United Nations Educational, Scientific and Cultural Organization, Paris. Observation year 2025. Accessed 2026-11-03.back
- 17Cornejo-Plaza, M.I., Cippitani, R. and Pasquino, V., Chilean Supreme Court ruling on the protection of brain activity: neurorights, personal data protection, and neurodata, Frontiers in Psychology 15, 27 February 2024 (reference record read). Frontiers Media, Lausanne. Observation year 2024. Accessed 2026-11-03.back
- 18Lee, B.H., Even Chile neurorights leave inferred mental data in a gray zone, Stanford Law School Law and Biosciences Blog, 27 April 2026 (blog page read; commentary, not a legal text). Stanford University, Stanford. Observation year 2026. Accessed 2026-11-03.back
- 31OECD (ed.), Recommendation of the Council on Responsible Innovation in Neurotechnology, OECD/LEGAL/0457, adopted 11 December 2019 (instrument text opened). Organisation for Economic Co-operation and Development, Paris. Observation year 2019. Accessed 2026-11-05.back
- 14Colorado General Assembly (ed.), HB24-1058 Protect Privacy of Biological Data (bill page read: signed 17 April 2024; effective 7 August 2024). Colorado General Assembly, Denver. Observation year 2024. Accessed 2026-11-03.back
- 25California Legislature (ed.), SB 1223 (Becker), Consumer privacy: sensitive personal information: neural data, Chapter 887, Statutes of 2024, chaptered 28 September 2024 (bill record read on CalMatters Digital Democracy; sponsor release of 27 September 2024: signed by the Governor, in effect 1 January 2025; the legislature page returned an access error). California Legislature, Sacramento. Observation year 2024. Accessed 2026-11-05.back
- 41Spivack, J. and Victory, C., State Neural Data Laws, Summer 2025 (Future of Privacy Forum chart, August 2025; Montana SB 163 adds neurotechnology data to the Genetic Information Privacy Act, effective 1 October 2025; Connecticut SB 1295 adds neural data to sensitive data under its data privacy act, most sections effective 1 July 2026). Secondary compilation; the state texts were not opened. Future of Privacy Forum, Washington. Observation year 2025. Accessed 2026-11-05.back
- 42Carey (ed.), Ley N 21.383: publican reforma constitucional para establecer el desarrollo cientifico y tecnologico al servicio de las personas (client alert, 3 November 2021; Law 21.383 published in the Diario Oficial on 25 October 2021; adds a final paragraph to Article 19 No. 1 on protecting brain activity and the information derived from it). Law firm summary; the official text page did not load. Carey, Santiago. Observation year 2021. Accessed 2026-11-05.back
- 39European Parliament and Council, Regulation (EU) 2017/745 of 5 April 2017 on medical devices, Annex XVI point 6 (equipment intended for brain stimulation that applies electrical currents or magnetic or electromagnetic fields that penetrate the cranium). Official Journal of the European Union L 117, 5 May 2017, Luxembourg. Observation year 2017. Accessed 2026-11-05.back
- 43European Parliament and Council, Regulation (EU) 2024/1689 of 13 June 2024 laying down harmonised rules on artificial intelligence (Artificial Intelligence Act), Article 5(1)(f) on AI systems to infer emotions in the workplace and education institutions, except for medical or safety reasons. Official Journal of the European Union, L series, 12 July 2024, Luxembourg. Observation year 2024. Accessed 2026-11-05.back
- 19Szoszkiewicz, L. and Yuste, R., Mental privacy: navigating risks, rights and regulation, EMBO Reports 26(14), 3469 to 3473, published online 25 June 2025 (reference record read; no abstract beyond the subtitle). Springer Nature, London. Observation year 2025. Accessed 2026-11-03.back
- 21Bublitz, C. et al., A moratorium on implantable non-medical neurotech until effects on the mind are properly understood, Neuroethics 18(3), article 46, 2025 (reference record read: proposes a mental impact assessment, a moratorium and a ban for children). Springer, Dordrecht. Observation year 2025. Accessed 2026-11-03.back
- 33Genser, J., Damianos, S. and Yuste, R., Safeguarding Brain Data: Assessing the Privacy Practices of Consumer Neurotechnology Companies (report for the Neurorights Foundation, April 2024; policy documents of 30 companies reviewed; no figure used). Neurorights Foundation, New York. Observation year 2024. Accessed 2026-11-05.back
- 34Yuste, R. et al., Four ethical priorities for neurotechnologies and AI, Nature 551, 159 to 163, 2017 (Crossref record). Springer Nature, London. Observation year 2017. Accessed 2026-11-05.back
- 35Ienca, M. and Andorno, R., Towards new human rights in the age of neuroscience and neurotechnology, Life Sciences, Society and Policy 13, 5, 2017 (Crossref record). Springer, Berlin. Observation year 2017. Accessed 2026-11-05.back